Pharming Group Expands Joenja's Pediatric Label Amid RUCONEST Revenue Decline
Pharming Group (NASDAQ:PHAR) announced that the U.S. Food and Drug Administration approved new dosing options for its drug Joenja, targeting children aged 4–11 with APDS who weigh at least 27 kilograms. The approval expands treatment access through higher tablet strengths of 40 mg and 50 mg, available in October via existing distribution channels. The expansion comes as Pharming Group's revenue mix shifts: Joenja’s second-quarter sales rose by 40% year-over-year to $17.9 million while RUCONEST declined by 10% to $72.3 million, contributing to a total revenue drop of 3%. Although Joenja is growing rapidly, the larger but declining RUCONEST franchise still dominates overall results. Pharming Group has also submitted an application for lower-dose pediatric formulations and expects potential stabilization in RUCONEST sales by late 2026. However, challenges remain as only a subset of identified APDS patients may be immediately eligible due to weight requirements.
Tickers: $PHAR